Skip to search formSkip to main contentSkip to account menu

AZD 4877

Known as: AZD-4877, AZD4877, KSP Inhibitor AZD4877 
A synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein… 
National Institutes of Health

Related topics

Related topics

3 relations
KIF11 protein, humanNegative Regulation of Cell CyclePositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML).
3580 Background: AZD4877 is a potent, specific inhibitor of Eg5 (kinesin spindle protein). The only known function of Eg5 is to… 
2012
2012
p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells
Antimitotics such as taxanes are being considered as alternatives to conventional cisplatin-based chemotherapy in patients with… 
2010
2010
Abstract 4429: Characterization of the kinesin spindle protein inhibitor AZD4877
The process of mitosis is a validated point of intervention in cancer therapy and a variety of anti-mitotic drugs are… 
2009
2009
THE MITOTOIC SPINDLE APPARATUS INHIBITOR AZD4877 HOLDS PROMISE AS A NOVEL THERAPEUTIC OPTION AGAINST HUMAN BLADDER CANCER
2008
2008
Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors
2501 Background: AZD4877 is a specific, potent inhibitor of Eg5 (kinesin spindle protein). The sole function of Eg5 is to… 
2008
2008
Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies
2516 Background: AZD4877 is a specific and potent inhibitor of the mitotic kinesin Eg5 with cytotoxicity to human tumor cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)